Robert Califf receives support from ​​54 organizations to be commissioner of the FDA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Fifty-four organizations involved in health care sent a letter to the Senate  leadership, urging confirmation of Robert Califf as FDA commissioner. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA issued a Complete Response Letter to Summit Therapeutics Inc. regarding the Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody.
FDA approved Wilserdly (giredestrant) in combination with everolimus for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.
FDA approved Imfinzi (durvalumab)​ in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. 
FDA granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login